FDA supply chain

Supply chain disruptions impacting medical markets have become a defining risk factor for healthcare delivery and biopharma commercialization in the United States. From raw material shortages to distribution bottlenecks, these disruptions are exposing structural vulnerabilities across pharmaceutical manufacturing, medical device production, and hospital procurement systems. As demand for complex therapies rises, supply chain resilience is … Read more